Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Invivyd, Inc.

NASDAQ: IVVD · Life Sciences · 3 alerts · CIK 1832038

Share price
$0.5377Close, Nov 16
Market cap
$159M
Shares outstanding
295.63MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Invivyd, Inc. filings on SEC EDGAR ↗

7:11 AM ET 10-Q
Financial Results

Invivyd Q3 2026 Results: Net Loss of $33.5M, Loss Widens

Invivyd, Inc. reported a significant increase in net loss to $119.3 million for the nine months ended September 30, 2026, compared to $41.4 million in the prior year, driven by a surge in R&D and SG&A expenses. Despite the higher loss, total revenue grew to $43.5 million from $36.2 million year-over-year, while cash and cash equivalents decreased to $126.4 million.

Key figure
Net loss $33.5M
7:09 AM ET 8-K
Financial Results

Invivyd Financial Results

Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.

Term
Q3 2026

“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”

Marc Elia, Chairman and Chief Executive Officer

“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”

Bill Duke, Chief Financial Officer
7:27 AM ET 8-K
Clinical Trial Data

Invivyd Clinical Trial Data

Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.

Earnings call
Sep 29, 2026, 8:30 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.